EAU

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Mercredi, mars 27, 2024
AAGL, Patient, TMS, Investment, Endometriosis, Therapy, USD, Marketing, Congress, Urology, Teaching hospital, INPI, Food, Prostate cancer, EAU, Cancer, Hospital, Intellectual property, AUA, FDA, Diagnosis, DIE, Growth, EDAP, Operating cost, EDT, Randomized controlled trial

Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.

Key Points: 
  • Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.
  • The increase was driven by 10 Focal One systems sold in the fourth quarter of 2023 versus 7 systems sold in the fourth quarter of 2022.
  • Total revenue in the Distribution business for the fourth quarter of 2023 was EUR 9.9 million (USD 10.7 million), as compared to EUR 6.7 million (USD 7.0 million) for the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was EUR 3.5 million (USD 3.8 million), compared to an operating loss of EUR 1.6 million (USD 1.6 million) in the fourth quarter of 2022.

Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts

Retrieved on: 
Lundi, avril 8, 2024
Biotechnology, Pharmaceutical, Managed Care, Oncology, General Health, Health, FDA, Clinical Trials, NMIBC, BCG, Toxicity, HG, Physician, Congress, Nadofaragene firadenovec, Survival, PD, Cystectomy, Ferring Pharmaceuticals, Patient, Aes, EAU, MD Anderson Cancer Center, University, Month, Carcinoma in situ, Safety, Division, Probability, CIS, Food, Pharmaceutical industry

“Intravesical gene therapy represents an important innovative treatment option for these patients.

Key Points: 
  • “Intravesical gene therapy represents an important innovative treatment option for these patients.
  • The efficacy analysis included 103 and 48 patients in the CIS and PD cohorts, respectively, who met the protocol definition of BCG-unresponsive NMIBC.
  • In total, 12.1% (13/107) and 20.0% (10/50) of patients in the CIS and PD cohorts, respectively, received ADSTILADRIN at three years.
  • In the CIS cohort, about 53% achieved a complete response (CR) at Month 3 in the primary analysis.

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Retrieved on: 
Vendredi, avril 5, 2024
Surgery, Genetics, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Congress, Cystectomy, CDX, Patient, Roche, DNA, DFS, EAU, Bladder cancer, MIBC, NTRA, Survival rate, MRD, FDA, Food, Pharmaceutical industry

The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.

Key Points: 
  • The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.
  • Sponsored by Genentech, a member of the Roche group, IMvigor011 is a global, double-blind, randomized, Phase III trial, in which high-risk MIBC patients are serially tested with Signatera for up to 12 months post cystectomy.
  • Patients who test Signatera MRD-positive at any point during the 12-month surveillance window are randomized to the anti-PDL1 atezolizumab (Tecentriq®) vs. placebo.
  • “We believe the results of this trial will further demonstrate how Signatera can help personalize treatment decisions and improve outcomes for bladder cancer patients.

Quanta System on the Peaks of the Urological Laser World Once Again: Quanta Magneto Technology™

Retrieved on: 
Vendredi, avril 5, 2024
Health, Medical Devices, Surgery, General Health, Research, Science, Biotechnology, Quanta, Sorbonne University, Lithotripsy, Magneto, Holmium, History, Prostate, EAU, Surgeon, Safety, Cancer, Multimedia, Computer data storage

View the full release here: https://www.businesswire.com/news/home/20240404169544/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240404169544/en/
    Cyber Ho Magneto with Quanta Magneto Technology™ (Photo: Business Wire)
    On the way to its 40th anniversary Quanta System remains steadfast in its mission: innovate to improve the lives of people around the world; with an unwavering belief that progress is always possible.
  • The global leader in laser technologies continually collaborates with medical professionals, working side by side with doctors to advance healthcare.
  • It is this commitment that drives the latest groundbreaking addition to the Cyber Ho family: Cyber Ho Magneto.
  • Cyber Ho Magneto, in fact, is the first laser system that tamed the peak power of holmium, turning it into a much longer pulse duration providing the superior dusting of a Thulium Fiber Laser.

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Retrieved on: 
Mercredi, mars 13, 2024
Taboo, Anxiety, Woman, Mental health, Ticker, Doctor of Philosophy, EAU, Neurostimulation, Urethra, MD, Pathology, Nursing, Quality of life, Female, Prostate, Urinary incontinence, Hope, Life, European, Health, Incontinence, Medtech, Patient, Disorder, Child, Male, European Association of Urology, Trial of the century, Ageing, Animation, Wound healing, Medical device

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Key Points: 
  • Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
  • This first implantation of the artificial urinary sphincter Artus was successfully performed by Prof. Roman Zachoval, MD, PhD, head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic, on a 68-year-old male with severe urinary incontinence.
  • “Artus is easy to prepare and implant due to its innovative design compared to the previous generation of urinary sphincters.
  • Artus is an implantable artificial urinary sphincter developed for the treatment of moderate to severe urinary incontinence in both men and women.

Autism Specialists to Host Grand Opening of New Wisconsin Clinic for Young Children

Retrieved on: 
Lundi, février 5, 2024
Pediatrics (journal), Spectrum, Diagnosis, American Academy, EAU, Chippewa Valley, ABA, Senior counsel, Communication, Hope, Caravel, Golden Joystick Awards, Social skills, Applied behavior analysis, Pediatrics, Nursing

EAU CLAIRE, Wis., Feb. 5, 2024 /PRNewswire/ -- Caravel Autism Health , a leader in the diagnosis and treatment of young children on the autism spectrum, is hosting a ribbon-cutting on February 6 to celebrate the grand opening of a new, state-of-the-art autism therapy clinic.

Key Points: 
  • EAU CLAIRE, Wis., Feb. 5, 2024 /PRNewswire/ -- Caravel Autism Health , a leader in the diagnosis and treatment of young children on the autism spectrum, is hosting a ribbon-cutting on February 6 to celebrate the grand opening of a new, state-of-the-art autism therapy clinic.
  • Caravel specializes in Applied Behavior Analysis therapy, which uses positive reinforcement to help children with autism improve a wide range of skills including communication and social skills.
  • "Providing access to high-quality therapy at a young age is how we ensure that children achieve the best possible outcomes.
  • "We change the lives of families touched by autism by helping children reach their full potential," explained Carly Burish, Caravel's Eau Claire clinic director.

Western Wisconsin Loses Health Systems, but Local Provider Smart Infusion Therapy Services Fills Gap in Care

Retrieved on: 
Mercredi, janvier 31, 2024
Multimedia, Clinical, Patient, EAU, Insurance, RN, Medical device

The professional nursing team at Smart Infusion is uniquely positioned to assist patients in seamlessly transitioning care from a closing hospital.

Key Points: 
  • The professional nursing team at Smart Infusion is uniquely positioned to assist patients in seamlessly transitioning care from a closing hospital.
  • Smart Infusion Therapy Services CEO, William Pickart has spent the last week meeting with employers and brokers throughout the impacted area.
  • Patients seeking care can call Smart Infusion Therapy Services - Eau Claire at (608) 690-7210, or to learn more visit: www.MySmartInfusion.com
    Smart Infusion Therapy Services Eau Claire is located at 3004 Golf Rd Suite 101B, Eau Claire, WI 54701, with additional locations in Weston and Middleton WI.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/western-wisconsin-loses-health-...
    SOURCE Smart Infusion Therapy Services, LLC

Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.

Retrieved on: 
Samedi, décembre 30, 2023
Neurostimulation, EAU, Woman, Medtech, Research, Male, Hope, Nursing, European, Health, Ageing, Urinary incontinence, Mental health, Anxiety, Incontinence, Prostate, Pathology, Aix-en-Provence, Patient, Ticker, Artus, Disorder, Female, Pharmaceutical industry

Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.

Key Points: 
  • Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.
  • Artus is an innovative device adapted for the treatment of incontinence in women and men.
  • Aix-en-Provence, 6 December 2023 – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specialising in the international development and industrialisation of innovative medical prostheses, is announcing the start of the European pilot study, Dry, with its Artus medical device for the treatment of urinary incontinence.
  • Publication of an international study by the European Association of Urology on the economic consequences of urinary incontinence in Europe.

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Retrieved on: 
Mardi, décembre 19, 2023
EAU, Partnership, Trust, Caregiver, Research, FDA, Acquisition, AUA, Prostate cancer, Doctor of Philosophy, Cancer, Growth, Patient, BPH, Therapy

CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell.

Key Points: 
  • CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell.
  • This past quarter has been transformative, marked by strategic shifts and notable achievements, all aimed at enhancing the value we bring to you as our shareholders.
  • To reflect our recent achievements and renewed oncology focus, we have rebranded as Onconetix, Inc.
  • Joining the senior management team of Onconetix will be Dr. Ralph Schiess, PhD, co-founder of Proteomedix, as Chief Science Officer, and Mr. Christian Brühlmann, co-founder of Proteomedix, as Chief Strategy Officer and General Manager of Europe.

Wisconsin College breaks student barriers as global leader of OER

Retrieved on: 
Jeudi, décembre 7, 2023
Ebook, Community college, Bureau of Labor Statistics, Creativity, OER, Workforce, RN, Learning, Student, Patient, Multimedia, EAU, Faculty, Textbook, Intelligence, Teaching, CVTC, CBS, News, Chippewa Valley Technical College, Wisconsin Technical College System, AACC, Dream, CBS News, AI, AER, Law enforcement, American Dream, Face, Human, WTCS, Education, Retail, Nursing

Over the last decade, the cost of college textbooks has risen four times faster than inflation, according to CBS News.

Key Points: 
  • Over the last decade, the cost of college textbooks has risen four times faster than inflation, according to CBS News.
  • According to Bureau of Labor Statistics data, textbook prices have risen more than 1,000 percent in the span of 40 years.
  • Since 2013, CVTC has been a leader in the development of open education resources (OER).
  • With these initiatives and our strong partnerships, we are rewriting the narrative of education, dismantling the barriers that have hindered progress.